Research press release


Nature Medicine

Antituberculosis boosters




A Baulardたちは、培養中でのエチオナミドの代謝活性化を10倍以上促進するEthR阻害剤を設計した。結核菌を感染させたマウスで調べたところ、これらの阻害剤の1つを利用すると、少量のエチオナミドを投与しても、従来通りの高投与量治療と同等の感染抑制効果がみられた。この新しいEthR阻害剤がもつ促進効果をきっかけに、エチオナミドや類似化合物を結核に対する第一選択薬として見直す動きが出てくるだろう。

Scientists have developed molecules for boosting the efficiency of an antibiotic used to treat tuberculosis, according to research published online this week in Nature Medicine. These new 'booster' drugs enable a small dose of an existing antituberculosis agent to work as well as conventional high dose treatment to fight off the infection.

Current tuberculosis therapy has side effects, which lead to a high risk of noncompliance with the treatment and to the emergence of drug-resistant bacteria.

Several antituberculosis compounds require metabolic activation before they can kill the bacteria. Drugs such as ethionamide, a second-line anti-tuberculosis compound, are activated by a bacterial enzyme known as EthA. The production of EthA is in turn controlled by a transcriptional repressor dubbed EthR.

Alain Baulard and colleagues designed inhibitors of EthR that boost the metabolic activation of ethionamide more than an order of magnitude in culture. In mice infected with tuberculosis, one of these inhibitors enabled a small dose of ethionamide to lessen the infection as efficiently as the conventional high-dose treatment. Owing to their boosting effect, the new inhibitors should prompt reconsideration of the use of ethionamide and related compounds as first-line anti-tuberculosis drugs.

doi: 10.1038/nm.1950


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。